After graduating from Queen Mary (University of London), with an undergraduate degree in molecular biology, Alex spent three years in the Immunoassay department at Huntingdon Life Sciences. He joined UCB-Celltech in 2008 and spend nine years working in the in vitro pharmacology department, ultimately becoming a Principal Scientist and Project Leader for various NCE projects. His work focused on creating orally bioavailable small molecules to allosterically modulate protein-protein interactions, which would normally be tackled by antibodies.
In 2018, UCB funded his self-designed PhD project. Working with Professor Jean van den Elsen at the University of Bath and Dr Alastair Lawson at UCB, the project focused on isolating mini domains from the ultralong CDRH3, which are unique to a subset of bovine antibodies, to create the smallest antibody fragments described to date and new modulators of Complement C5. This work won him the UCB Pat Talaga award for the most innovative scientist in 2019. He currently works in the Immunology Therapeutic Area at UCB, as a Senior Principal Scientist.